Mode
Text Size
Log in / Sign up

High-dose vitamin D shows no superior effect over low-dose for Major Depressive DisorderTesting High Dose Vitamin D for Treatment of Major Depressive Disorder

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that high-dose vitamin D (4000 IU) shows no superior effect over low-dose (400 IU) for Major Depressive Disorder.

This randomized controlled trial enrolled 281 outpatients aged 18 to 65 years with mild to severe depression episodes in Finland. The study aimed to evaluate the efficacy of cholecalciferol as an adjunctive treatment over a six-month period.

The intervention group received high-dose vitamin D (100 μg / 4000 IU) daily, while the comparator group received low-dose vitamin D (10 μg / 400 IU) daily. Both groups received these doses as adjunctive therapy to their existing treatment regimens.

Primary outcome data were available for 234 patients (118 in the high-dose group and 116 in the low-dose group). Results showed no superior effect of higher vitamin D supplementation compared to lower vitamin D supplementation on Montgomery-Åsberg Depression Rating Scale (MADRS) scores. The Cohen's d was -0.09 (95% CI -0.32 to 0.14), which was not statistically significant.

Safety data, including adverse events and discontinuation rates, were not reported. The study suggests that increasing the dose of cholecalciferol does not provide additional clinical benefit for depressive symptoms in this population.

How this fits prior evidence

How this fits prior evidence: This finding addresses a gap regarding nutritional supplements as adjunctive therapies for Major Depressive Disorder. While other covered interventions like transcranial direct current stimulation, second-generation antipsychotics, and antidepressant-antipsychotic combinations have shown varying degrees of efficacy or response rates in MDD, this study specifically indicates that higher doses of cholecalciferol do not provide a superior effect over lower doses.

Researchers conducted a study in Finland to see if taking extra vitamin D could improve symptoms for people living with major depression. The study looked at patients between the ages of 18 and 65 who were already receiving standard medical care.

The participants were split into two groups. One group received a high dose of vitamin D every day for six months, while the other group received a much lower daily dose. Both groups continued their regular treatments during the study period.

The results showed that the higher dose did not provide better relief from depression than the lower dose. Patients in both groups saw similar changes in their mood and symptoms over the half-year period.

This means that while vitamin D is important for health, taking a very high amount does not seem to offer extra benefits for those struggling with depression compared to a standard low dose.

What this means for you:
High doses of vitamin D did not provide better relief from depression than lower doses in this study.

Common questions

Does taking a higher dose of vitamin D help depression more than a lower dose?

In this six-month trial, no. Adults with depression who took 4000 IU of vitamin D daily did not show greater improvement in depression scores than those taking 400 IU. The difference between groups was not statistically significant.

Who was included in the vitamin D and depression study?

The study included 281 outpatients aged 18 to 65 who were experiencing a mild to severe depressive episode. All were already receiving treatment for depression and were given either a high or low dose of vitamin D as an add-on.

What were the side effects of taking high-dose vitamin D in this trial?

The study did not report on side effects, serious adverse events, or how well participants tolerated the supplements. So, we do not have information about safety from this trial. Always consult your doctor about potential risks.

Study Details

Study typeRct
Sample sizen = 281
EvidenceLevel 2
PublishedAug 2026
View Original Abstract ↓
BACKGROUND: Initial studies suggest vitamin D (VD) supplementation may aid in treating major depressive disorder, but rigorous randomised controlled trials are needed. TRIAL DESIGN: DepFuD trial was a six-month, double-blinded, parallel-group, randomised controlled superiority design trial with a 1:1 allocation ratio. Outpatients with mild to severe depression episode, aged 18-65 years, were included. METHODS: The primary aim was to compare the effects of low-dose versus high-dose VD as adjunctive to participants' existing depression treatments, hypothesising that the high-dose group would show greater symptom reduction over six months. Participants were randomised to receive either 100 μg (4000 IU) or 10 μg (400 IU) of VD (cholecalciferol) daily for six months. The primary outcome was measured by between-group differential change over six months in the Montgomery-Åsberg Depression Rating Scale (MADRS) score (range: 0-60). Data was collected in Finland between November 2015 and December 2020. RESULTS: A total of 281 participants were randomised: 142 in the low-dose and 139 in the high-dose group. At baseline, 46% of the participants in low-dose and 42% in high-dose group had VD deficiency (<50 nmol/l). Primary outcome data were available for 234 participants (116 in low-dose and 118 in high-dose). The standardised adjusted MADRS mean difference was small and non-significant (Cohen's d = -0.09; 95% CI -0.32 to 0.14). CONCLUSIONS: The six-month trial demonstrated no superior effect of the higher VD supplementation compared to the lower VD supplementation on depressive symptoms. REGISTRATION: ClinicalTrials.gov: NCT02521012. DepFuD was supported by Finnish State Research Funding (VTR).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.